PDCD1 and head and neck squamous cell carcinoma: Recently, programmed cell death protein 1 (PD1) blockade immunotherapy combined with chemotherapy received approval for the first-line of treatment for recurrent and metastatic head and neck squamous cell carcinoma (HNSCC).